Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
The SELECT cardiovascular outcomes trial (N=17,604), published in NEJM 2023 (DOI: 10.1056/NEJMoa2307563), demonstrated a 20% reduction in major adverse cardiovascular events (MACE) -- the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke -- in overweight or obese adults without diabetes
Lilly has submitted orforglipron to the FDA for the treatment of obesity, but Canadian regulatory submission status hasnt been publicly confirmed
Important caution: Given the dual role of glutathione in cancer biology, glutathione or NAC supplementation should NOT be taken during active cancer treatment without oncologist approval, as it could theoretically protect tumor cells from therapy [2][5]
Do not discontinue GLP-1 medications without medical guidance, as this may worsen blood glucose control or cause weight regain
This finding is particularly significant as it demonstrates that the cardiovascular benefits of GLP-1 agonists extend beyond their glucose-lowering effects to encompass direct cardiovascular protection in obesity
Get the best of Found right in your inbox Get started with Found Ready to lose weight and live your healthiest life?
US$ 27.09
US$ 28.76
US$ 25.21
US$ 28.74
)
US$ 27.32
US$ 26.96
